XenoPort Inc (XNPT)

7.07
0.05 0.71
Prev Close 7.02
Open 7.04
Day Low/High 7.02 / 7.07
52 Wk Low/High 3.35 / 7.86
Volume 2.62M
Avg Volume 1.64M
Exchange
Shares Outstanding 63.53M
Market Cap 449.13M
EPS -1.30
Div & Yield N.A. (N.A)

XenoPort, AMICAS: Early Volume Plays

A handful of stocks trading near $10 were poised to move on above-average volume during Monday's regular session.

Top Takes: XNPT, WMT, AMAT

Here's what some of our market pros are saying and playing.

Early Volume Movers: XenoPort, DepoMed

Early Volume Movers: XenoPort, DepoMed

A handful of stocks trading below $10 were poised to move on above-average volume during Thursday's trading session.

10 Biotech Stocks Facing FDA Approval

News about FDA drug approvals and rejections can send biotech stocks rocketing or plummeting. Here are ten companies facing FDA approval decisions this year.

XenoPort To Release Fourth Quarter Financial Results On February 22, 2010

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its fourth quarter financial results on February 22, 2010 at approximately 4:30 p.

XenoPort Announces Extension Of The Horizant™ PDUFA Date To February 11, 2010

XenoPort Announces Extension Of The Horizant™ PDUFA Date To February 11, 2010

XenoPort, Inc. (Nasdaq:XNPT) announced today that the U.

XenoPort Announces Horizant™ As Brand Name For XP13512

XenoPort Announces Horizant™ As Brand Name For XP13512

XenoPort, Inc. (Nasdaq: XNPT) announced today that, subject to the approval of the U.

Biotech Calendar: Key Dates for February

Biotech Calendar: Key Dates for February

February's list of important, potentially stock-moving biotech events.

FDA Delays Cadence Drug Review: BioBuzz

FDA Delays Cadence Drug Review: BioBuzz

IV Acetaminophen review pushed back to February 2010.

Correction: XenoPort-Glaxo Drug

Correction: XenoPort-Glaxo Drug

Correction: XenoPort-Glaxo drug

Glaxo, XenoPort Drug To Get Longer FDA Review

GlaxoSmithKline, XenoPort drug candidate gets extended FDA regulatory review

Doc Offers Top Hep C Drug Picks: BioBuzz

Doc Offers Top Hep C Drug Picks: BioBuzz

Vertex, InterMune, Pharmasset get positive reviews after recent Hep C meeting.

Xoma Waffles on Timing of Drug Partnership: BioBuzz

An expected deal for its diabetes drug may not happen until next year.

FDA Extends Review Of XenoPort-Glaxo Pain Drug

XenoPort and Glaxo says FDA review of neuropathic pain drug extended 3 months, to Feb. 2010

Ariad Upgraded, Xenoport Drug Delayed: BioBuzz

Ariad Upgraded, Xenoport Drug Delayed: BioBuzz

Analysts sees upside in two Ariad drugs while FDA delays decision on Xenoport drug.

Depomed Says Shingles Pain Drug Meets Study Goal

Depomed Says Shingles Pain Drug Meets Study Goal

Depomed says its post-shingles pain drug succeeded it trial, and shares hit three-year high

XenoPort Shares Dip On Diabetic Drug Study Failure

XenoPort shares fall as diabetic pain drug fails to meet goal in midstage clinical trial

XenoPort, Glaxo Pain Drug Fails In Midstage Study

XenoPort, GlaxoSmithKline pain drug fails to meet treatment goal in midstage clinical trial

XenoPort Says FDA Accepts New Solzira Application

XenoPort Says FDA Accepts New Solzira Application

XenoPort and Glaxo say FDA accepts new application for Solzira; XenoPort will be paid $23M

Health Winners & Losers: King Pharmaceuticals

Health Winners & Losers: King Pharmaceuticals

King Pharmaceuticals drags health stocks lower after missing on second quarter earnings.

Health Winners & Losers: AstraZeneca

AstraZeneca climbs on a MedImmune contract.

TSC Ratings' Upgrades, Downgrades: Owens Corning

TSC Ratings' Upgrades, Downgrades: Owens Corning

Presidential Life, Home Bancshares, Owens Corning, Transdigm and Xenoport upgraded.

Health Winners & Losers: Barr

Barr Pharma slides on an earnings miss.

Feuerstein's Biotech-Stock Mailbag: Navigating the Sector Swoon

Feuerstein's Biotech-Stock Mailbag: Navigating the Sector Swoon

The pros see more trouble ahead.

Stock Upgrades, Downgrades From TheStreet.com Ratings

Foundation Coal, United Stationers, Diana Shipping upgraded; Arbitron, Xenoport downgraded.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

BioScrip climbs on an analyst upgrade.

Tuesday's Health Winners & Losers

Arena gets an upgrade by a analyst with a positive safety outlook.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Biotech and health stocks traded mixed on uneven earnings news.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Luminex is higher.